Accord BioPharma

What Accord BioPharma does

Accord BioPharma, Inc. is the U.S. specialty pharmaceutical division of India-based Intas Pharmaceuticals, Ltd., founded in 2021 and headquartered in Raleigh, North Carolina. The company develops, acquires, and commercializes FDA-approved biosimilars and specialty therapies targeting oncology, immunology, and critical care indications. Its commercial portfolio includes six FDA-approved biosimilars: UDENYCA (pegfilgrastim-cbqv, acquired from Coherus BioSciences), HERCESSI (trastuzumab-strf), IMULDOSA (ustekinumab-srlf), OSVYRTI and JUBEREQ (denosumab-desu), FILKRI (filgrastim-laha), and IMMGOLIS/IMMGOLIS INTRI (golimumab-sldi), plus the specialty pharmaceutical CAMCEVI (leuprolide) for advanced prostate cancer.

The company targets oncologists, urologists, rheumatologists, and gastroenterologists through field sales representatives, healthcare provider engagement, and distribution/GPO partnerships. It distributes through specialty pharmacy networks including a captive Accord Specialty Pharmacy, and has secured preferred formulary status with major payers Cigna Healthcare and Express Scripts. The company pursues aggressive biosimilar pricing strategies, exemplified by IMULDOSA launching at a 92% discount to STELARA reference pricing, paired with patient support infrastructure via the AccordCares program (co-pay assistance, benefits investigation, prior authorization support) and the AccordConnects mobile application for HCP inventory management.

Revenue derives from one-time product sales of FDA-approved biosimilar and specialty pharmaceutical products in the U.S. market, with strategic plans to expand to 20 biosimilar launches by 2030. The company recently expanded its geographic footprint through an October 2025 licensing agreement extending BAT2506 (golimumab biosimilar) rights to Canada. Revenue figures are not publicly disclosed.

Name

Accord BioPharma

Legal name

Accord BioPharma, Inc.

Website

https://accordbiopharma.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

101–250 employees

Short description

Accord BioPharma is the U.S. specialty division of Intas Pharmaceuticals, commercializing FDA-approved biosimilars and specialty therapies in oncology, immunology, and critical care for healthcare providers, payers, and patients across the United States.

Ownership category

akta.pro rank

Product category

Specialty Biopharmaceuticals / Biosimilars

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Monoclonal Antibody (mAb) Biosimilars (HLAIAFAA), Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Oncology Biosimilars (HLAAAHAG)

Keywords

• Biosimilar pharmaceuticals
• Oncology therapeutics
• Immunology biologics
• Specialty pharmaceuticals
• G-CSF supportive care

Headquarters

HQ city

Durham

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Marketing or Sales, Personnel, Operations

Revenue model

1. Pharmaceutical Product Sales: Accord BioPharma generates revenue through the sale of FDA-approved biosimilar and specialty pharmaceutical products in the U.S. market, including oncology supportive care, immunology, and critical care therapies.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Core offering

Accord BioPharma is the U.S. specialty pharmaceutical and biosimilars division of Intas Pharmaceuticals. It acquires, develops, and commercializes FDA-approved biosimilars and specialty therapies in oncology, immunology, and critical care, including the proprietary ready-to-inject leuprolide product CAMCEVI, and biosimilars referencing reference biologics such as STELARA, Neulasta, NEUPOGEN, Herceptin, Prolia/Xgeva, and Simponi/Simponi Aria. Its portfolio is sold through specialty pharmacies, distribution/GPO partners, and payers, and is complemented by patient and HCP support programs (AccordCares, AccordConnects).

Product overview

Accord BioPharma is a U.S. specialty pharmaceutical division of Intas Pharmaceuticals focused on developing, acquiring, and commercializing biosimilars and specialty therapies in oncology, immunology, and critical care. Their portfolio consists of FDA-approved biosimilars including IMULDOSA (ustekinumab), FILKRI (filgrastim), HERCESSI (trastuzumab), UDENYCA (pegfilgrastim), OSVYRTI and JUBEREQ (denosumab), and IMMGOLIS/IMMGOLIS INTRI (golimumab). The portfolio is complemented by the specialty pharmaceutical CAMCEVI (leuprolide) for advanced prostate cancer. These products are supported by patient and provider support programs including AccordCares and AccordConnects. The company aims to launch 20 biosimilar products by 2030.

Differentiator

Problem solved

Functional benefit

Brands

• AccordCares: Patient support program offering co-pay assistance, patient assistance, benefits investigation, prior authorization support, billing and coding information, and alternate coverage identification for eligible patients.
• AccordConnects

Products and services

• CAMCEVI (leuprolide) 42mg injectable emulsion Injectable emulsion for treatment of adult patients with advanced prostate cancer; first ready-to-inject sterile formulation of leuprolide mesylate for subcutaneous injection, every-six-months dosing via a prefilled syringe.
• IMULDOSA (ustekinumab-srlf) Biosimilar to STELARA (ustekinumab) for moderate to severe plaque psoriasis, active psoriatic arthritis, Crohn's disease, and ulcerative colitis in adults and pediatric patients 6 years and older; available as prefilled syringes (45mg/0.5mL, 90mg/mL) and vials (130mg/26mL).
• UDENYCA (pegfilgrastim-cbqv) Biosimilar to Neulasta (pegfilgrastim) for reducing the incidence of infection (febrile neutropenia) in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs; available in three administration options (autoinjector, on-body injector, and prefilled syringe).
• HERCESSI (trastuzumab-strf) Biosimilar to Herceptin (trastuzumab) for HER2-overexpressing breast cancer and metastatic gastric cancer.
• FILKRI (filgrastim-laha) Biosimilar to NEUPOGEN (filgrastim) approved for cancer patients receiving myelosuppressive chemotherapy, acute myeloid leukemia patients, bone marrow transplant recipients, severe chronic neutropenia patients, and patients exposed to myelosuppressive radiation.
• OSVYRTI (denosumab-desu) Biosimilar to Prolia (denosumab) for treatment of postmenopausal women with osteoporosis at high risk for fracture, men with osteoporosis, glucocorticoid-induced osteoporosis, bone loss from androgen deprivation therapy for prostate cancer, and bone loss from adjuvant aromatase inhibitor therapy for breast cancer.
• JUBEREQ (denosumab-desu) Biosimilar to Xgeva (denosumab) for prevention of skeletal-related events in patients with multiple myeloma and bone metastases from solid tumors, giant cell tumor of bone, and hypercalcemia of malignancy refractory to bisphosphonate therapy.
• IMMGOLIS (golimumab-sldi) First FDA-approved biosimilar to Simponi (golimumab) for treating adults with moderately to severely active rheumatoid arthritis and ulcerative colitis; designated interchangeable for both indications.
• IMMGOLIS INTRI (golimumab-sldi) First FDA-approved biosimilar to Simponi Aria (golimumab) for treating adults with moderately to severely active rheumatoid arthritis and ulcerative colitis; designated interchangeable for both indications.
• AccordCares Patient support program offering Co-pay Assistance, Patient Assistance, Benefits Investigation, Prior Authorization, Billing and Coding Information, and Alternate Coverage Identification for eligible patients prescribed Accord BioPharma medicines.
• AccordConnects Mobile application designed to help healthcare providers manage in-practice inventory of CAMCEVI and access clinical information.

Quantifiable outcome

• IMULDOSA reduces cost by 92% compared to STELARA reference product
• +4 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Seven partnerships are on record, tiered core and minor.

• Coherus BioSciences, Inc.coreStrategic or Co-development Partner · 1 April 2025Acquisition of UDENYCA (pegfilgrastim-cbqv) franchise from Coherus BioSciences, including UDENYCA prefilled syringe, autoinjector, and on-body injector products. Key Coherus employees across Sales, Marketing, Finance, Supply Chain, and Quality joined Accord BioPharma to ensure supply and services continuity.
• Bio-Thera SolutionscoreStrategic or Co-development Partner · 1 February 2025February 2025 exclusive U.S. commercialization and license agreement for BAT2506, a golimumab biosimilar candidate referencing Simponi. Bio-Thera maintains responsibility for development, manufacturing, and supply while Accord holds exclusive rights to commercialize in the U.S. This partnership was expanded in October 2025 to include Canada commercialization rights.
• Foresee Pharmaceuticals, Co. LTDcoreOEM/ Whitelabel/ Licensing PartnerCAMCEVI is a registered trademark of Foresee Pharmaceuticals used under a license with Accord BioPharma. CAMCEVI (leuprolide) 42 mg injectable emulsion was developed by Foresee and licensed to Accord for U.S. commercialization.
• ZERO Prostate CancerminorGTM or Marketing PartnerPartnership with leading national nonprofit working to end prostate cancer and help all who are impacted, to create change at community level and beyond through the PRO.STATE of Mind campaign.
• StoryMDminorGTM or Marketing PartnerPartnership with StoryMD to provide physicians and patients compelling and personally curated content for advanced prostate cancer at the point-of-care through StoryMD's platform.
• Accord Specialty PharmacyminorChannel Partner/ Reseller/ DistributorIndependent specialty pharmacy based in Central Florida named finalist in MMIT's Retail Specialty Pharmacy Patient Choice Awards. Provides personalized, patient-centered specialty pharmacy services.
• Intas Pharmaceuticals, Ltd.coreOthersAccord BioPharma is the U.S. specialty division of Intas Pharmaceuticals. Intas provides manufacturing capabilities, regulatory expertise, and global operational support. Accord BioPharma leverages Intas' 40+ years of global expertise in oncology, immunology, and critical care.

Scale indicators6 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Coherus BioSciences: Direct biosimilar competitor; sold its UDENYCA franchise to Accord BioPharma in April 2025. Competes in pegfilgrastim and other oncology supportive care biosimilars, providing a like-for-like strategic and operational benchmark.
• Biocon Biologics: Global biosimilar developer and commercializer with strong oncology and immunology biosimilar portfolio, including products referencing trastuzumab, pegfilgrastim, and insulin. Competes directly with Accord across multiple molecule references.
• Alvotech: Pure-play biosimilar developer with a portfolio spanning oncology, immunology, and ophthalmology biosimilars including ustekinumab, adalimumab, and aflibercept. Competes head-to-head with Accord in the U.S. biosimilar market.
• Celltrion: Korean biopharmaceutical company and one of the world's leading biosimilar developers with multiple FDA-approved biosimilars including infliximab, rituximab, trastuzumab, and bevacizumab. Direct competitor across the biosimilar space.
• Samsung Bioepis: Joint venture between Samsung Biologics and Biogen developing biosimilars in immunology, oncology, and ophthalmology including etanercept, infliximab, adalimumab, trastuzumab, and ranibizumab. Direct biosimilar competitor.
• Amneal Pharmaceuticals: U.S. specialty and generics pharmaceutical company with a growing biosimilars business (e.g., pegfilgrastim) and overlapping focus on oncology, immunology, and critical care therapeutic categories where Accord BioPharma competes.

Broad incumbents

• Sandoz (Novartis): Global leader in biosimilars and generics with the largest biosimilar portfolio in the industry. Sandoz competes broadly across multiple biosimilar categories including oncology supportive care and immunology that overlap with Accord's portfolio.
• Viatris: Global healthcare company with a biosimilar portfolio including pegfilgrastim, trastuzumab, and rituximab. Competes with Accord in oncology biosimilars while operating a much broader specialty, generic, and branded pharma business.
• Pfizer (Hospira): Through its Hospira acquisition and continued investment, Pfizer is a major biosimilar player with approved biosimilars across infliximab, rituximab, trastuzumab, and oncology supportive care. Operates as part of Pfizer's broader biopharmaceutical portfolio.

Regional players

• Fresenius Kabi: Global healthcare company expanding its U.S. biosimilars portfolio including pegfilgrastim. While headquartered in Germany, its U.S. operations directly compete with Accord in oncology supportive care biosimilars.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xtwitter.com/accordbiopharma
• LinkedInlinkedin.com/company/accord-biopharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Accord BioPharma